Adult patients with acute lymphoblastic leukemia (ALL) and t(1;19)/E2A-PBX1 or t(4;11)/MLL-AF4 have a poor outcome. We have evaluated the impact of an intensified post-remission therapy using a high-dose chemotherapy course followed by allogeneic or autologous SCT on the outcome of 58 patients with t(1;19)/E2A-PBX1 (E2A group, n ¼ 24) or t(4;11)/MLL-AF4 (MLL group, n ¼ 34) treated in the LALA-94 multicenter prospective study. Patients in the MLL group had higher WBC counts and more frequent DIC. CR rates achieved by MLL and E2A groups were similar to other B-cell ALL (87, 82 and 86% respectively). While in CR, patients with a donor were assigned to alloSCT (n ¼ 22), the remaining patients with were randomized between autoSCT (n ¼ 15) or chemotherapy (n ¼ 8). Fiveyear overall survival was 31 and 45% for E2A and MLL groups, respectively. In both groups, DFS was higher in the alloSCT arm as compared to autoSCT and chemotherapy arms. The results of this study show that chemotherapy intensification did not overcome the poor prognosis of adults with t(1;19)/E2A-PBX1. Allogeneic SCT should thus be offered in first CR to patients with t(1;19)/E2A-PBX1 or t(4;11)/MLL-AF4. New therapeutic approaches are needed for patients without donor.
Introduction
The significant progress that has been made in the treatment of adult acute lymphoblastic leukemia (ALL) is due to the use of more intensive chemotherapy regimens [1] [2] [3] [4] and to risk-adapted strategies. 5, 6 Different stratification systems have been developed in order to tailor treatment. They were based on variables of prognostic importance such as age, initial leukocytosis, immunophenotype, the number of induction courses for CR and cytogenetics. 2, [5] [6] [7] Cytogenetic abnormalities are found in 50-60% of adult cases of ALL. [8] [9] [10] [11] The most frequent in adults is the Philadelphia chromosome (Ph) which is present in 30-40% of patients 1 and is now identified as an entity among ALLs. Indeed, Ph þ ALLs have specific clinico-biological characteristics, a poor prognosis, 12 and respond to Imatinib Mesylate, a tyrosine kinase inhibitor which specifically targets the BCR/ABL fusion protein present in Ph þ ALLs. 13, 14 Translocations t(1;19)/E2A-PBX1 and t(4;11)/MLL-AF4 are found in approximately 10% of adult patients and represent the second most frequent structural cytogenetic abnormalities of adult ALL. Both have been associated to a poor prognosis in children and adults. 15, 16 However, recent pediatric studies have shown that the use of intensive chemotherapy regimen was able to overcome the poor outcome of patients with t(1;19)/E2A-PBX1 raising the issue of allogeneic stem cell transplantation (SCT) in first complete remission. 17 The use of molecular diagnostic techniques contributes to a more exhaustive identification of patients with fusion transcripts including t(1;19)/E2A-PBX1 or t(4;11)/MLL-AF4. In the LALA-94 prospective study, all the samples obtained from the patients at the time of diagnosis were analyzed using RT-PCR in addition to conventional cytogenetics. RT-PCR was performed in a network of molecular laboratories that used standardized methods. Per protocol, the patients found positive for t(1;19)/E2A-PBX1 or t(4;11)/MLL-AF4 were assigned to the high-risk stratum of the study. Accordingly, they were scheduled to receive an intensified consolidation course and then assigned to allogeneic SCT, when a HLA identical sibling was available, or randomized to receive autologous SCT or conventional chemotherapy maintenance. 18 In the present study, we assessed the impact of intensified therapeutic strategies on the outcome of 58 adult patients with t(1;19)/E2A-PBX1 and t(4;11)/MLL-AF4 positive ALL included in the LALA-94 protocol.
Patients and methods

Patient selection
Eligibility criteria for the LALA-94 protocol were: morphologic and cytochemical confirmed diagnosis of ALL (mature B-cell ALL not included); newly diagnosed and previously untreated disease; no prior malignancy, severe prior illness or psychiatric disease; written informed consent.
Molecular biology analysis
Samples were obtained at diagnosis for all the patients included in the LALA94 trial. Follow-up samples were collected on days 35 (after the first induction course) 95 and 120 in patients with MLL-AF4 and E2A-PBX1 rearrangements. In the 1994-1996 period, RT-PCR for MLL-AF4 and E2A-PBX1 was performed in six laboratories which used published primer sequences. [19] [20] [21] In the 1997-2000 period, 16 laboratories performed RT-PCR and used the standardized BIOMED-1 primers according to the protocol described by van Dongen et al. 22 A specificity control of the amplified products was performed by Southern blot or by hybridization with an internal probe.
RQ-PCR was retrospectively performed on 47 samples from 14 patients with MLL-AF4 and 36 samples from six patients with E2A-PBX1. Briefly, cDNA synthesis and RQ-PCR for ABL (control gene), E2A-PBX1 and MLL-AF4 transcripts were performed according to the EAC protocol mainly using the 7700 machine (ABI, Foster City, CA, USA) as previously described. 23, 24 Standard curves for quantification were constructed using plasmid dilutions ranging from 10 5 to 10 copies (Ipsogen, France) and allowed the determination of copy numbers (CN) for each transcript. To correct for the variations in RNA quantity, results of RQ-PCR amplifications were expressed as the ratio of the fusion transcript CN/control gene CN, also called normalized copy number (NCN). Samples with ABL CN lower than 1000 were considered as poor quality samples for amplification and were discarded. This was the case for 12 MLL-AF4 samples (25%) and of 16 E2A-PBX1 samples (45%).
The MLL-AF4 samples that were analyzed included 17 diagnosis samples (eight bone marrow, six peripheral blood and two peripheral blood or bone marrow) and 30 follow-up samples (six peripheral blood samples, 18 bone marrow samples and six bone marrrow or peripheral blood samples). E2A-PBX1 samples included nine obtained at diagnosis (six peripheral blood and three bone marrow) and 27 follow-up samples (16 peripheral blood and 11 bone marrow).
Treatment
Details of the protocol have been previously described. 18 Briefly, after registration, patients were randomized to receive induction chemotherapy using either daunorubicin or idarubicin. Based on initial characteristics and response to induction chemotherapy (see Table 1 ), patients were stratified into four groups: (1) standard-risk ALL, (2) high-risk ALL, (3) Philadelphia chromosome positive ALL (Ph þ ALL) and (4) CNS-positive ALL. Based on these criteria, the patients with E2A-PBX1 and MLL-AF4 who are the scope of the present study were systematically assigned to the high-risk ALL group (group 2). Post-remission treatments for each group were as follows:
1. Patients with standard-risk ALL (group 1) were randomized to receive an intensive consolidation course with high-dose aracytine and mitoxantrone (HAM regimen) or a conventional consolidation with standard dose cytarabine, cyclophosphamide and 6-mercaptopurine. They were then scheduled to receive 2 years of maintenance chemotherapy. 2. All other patients (groups 2, 3 and 4) received one course of intensive consolidation or salvage (if not in CR after the first induction course) with HAM. Patients in CR and eligible for stem cell transplantation (SCT) were assigned to (i) allogeneic SCT if they had a matched related donor; (ii) autologous SCT for all patients in groups 3 and 4 in the absence of a matched related donor; and (iii) randomized between autologous SCT and maintenance chemotherapy for the patients of group 2 (high-risk) in the absence of a matched related donor.
Response criteria
Complete remission (CR) was defined as bone marrow blasts lower than 5% with a cellularity 425%, neutrophils above 1.5 g/l and platelet counts above 150 g/l in the absence of extramedullary disease. Failure included early deaths and resistant disease. Relapse was defined as the reappearance of leukemic cells in the bone marrow (45% blasts) and/or reappearance of clinical evidence of the disease.
Statistical analysis
Comparisons between study groups and associations between pretreatment patients' characteristics and response to treatment were evaluated by the Pearson w 2 test. All tests were two-sided with statistical significance set at 0.05. All analyses were performed on an intention-to-treat basis so that patients randomly assigned to any treatment group who never received the allocated treatment were not excluded from analysis. Overall survival (OS) was defined as the time from study entry to death or last patient contact. Disease-free survival (DFS) was defined from the date of CR to the date of relapse or death whichever came first, or last contact with patients in continuous CR. OS and DFS distributions were estimated by the method of Kaplan and Meier. Treatment and sub-groups comparisons were performed by the log-rank test. Simultaneous effects of multiple covariates were estimated with the maximum likelihood logistic regression model for response and the Cox model for DFS and OS and tested by the likelihood-ratio test, also used in univariate analyses for continuous variables. All computations were made 
Results
Among the 814 patients included in the LALA-94 study for whom cytogenetic or molecular biology data were available, we recorded 24 patients (4%) with t(1;19)/E2A-PBX1 and 34 patients (6%) with t(4;11)/MLL-AF4.
Patients with t(4;11)/MLL-AF4 Clinical and biological presentation. The clinical and biological presentation of t(4;11)/MLL-AF4 patients was compared to that of 325 patients with other types of non Ph þ B-cell ALL. The results presented in Table 2 show that patients with t(4;11)/MLL-AF4 had significantly higher WBC counts, higher LDH levels and more frequent disseminated intravascular coagulation (DIC) (41 versus 5% for other B-ALL). The immunophenotypic profile of these 34 patients is presented in Table 3 . The majority of cases (30/33 tested patients, 91%) were CD19 þ /CD10À, and 53% classified as EGIL B-I. 25 Of note, six cases were definitely B-III with significant cytoplasmic mu chain expression, and six were either B-I or B-III as mu chain expression was not assessed. In half the cases (17/33 tested), blasts expressed CD34 and all were HLA-DR positive. Only two patients showed aberrant expression of CD33. There was no aberrant expression of T-lineage markers.
Outcome. Results are detailed in Table 4 . Twenty-eight patients (82%) achieved CR after one (93%) or two (7%) induction courses. The CR rate was not different from other Ph-B-cell ALL. The 28 patients in CR were randomly assigned to allo SCT, autologous SCT or maintenance chemotherapy as shown in Table 3 . With a median follow-up of 45 months, 12 patients are alive, all being in continuous CR.
The 5-year DFS and OS were not statistically different from the other Ph-high-risk B-ALL (Figure 1) . Five-year DFS by treatment assignment in the MLL-AF4 group was 66713, 11710 and 20717% for allo-SCT, auto-SCT and chemotherapy, respectively (P ¼ 0.02) as shown in Figure 2 . Allogeneic SCT was thus associated with a significantly improved DFS with a plateau at 18 months. Only one patient in the auto-SCT group Abbreviations: LDH, lactate dehydrogenase; WBC, white blood cells; DIC, disseminated intravascular coagulation.
Table 3
Immunophenotypic data
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and one patient in the chemotherapy group achieved durable CR ( þ 24 and þ 46 months).
Molecular characteristics. Patients with t(4;11)/MLL-AF4
were identified using both cytogenetics and PCR in 30 patients (88%) and by PCR only in four patients (12%). The most frequent variant was the MLLe9-AF4e4 variant that was detected in 17 patients (50%). Alternative splicing led to the presence of two or three different MLL-AF4 transcripts per case. When assessed using quantitative PCR in the available samples, 9/11 (80%) non MLLe9-AF4e4 variants could be quantified using EAC primers. The mean normalized copy number (NCN) was 0.79 (range 0.09-5.1). There was no correlation between the diagnostic mean NCN level and outcome.
Molecular follow-up was available for 11 patients on day 30 that is following remission induction. The four patients (36%) who had positive RT-PCR have relapsed. Of the seven patients (64%) who had negative RT-PCR, three (42%) relapsed, a rate not different from the overall relapse rate in this cytogenetic group (48%). Follow-up RQ-PCR data were available for six patients. Only one case with MLLe9-AF4e4 fusion transcript was informative ( Figure 3 ) and showed that molecular relapse preceded clinical relapse.
Patients with t(1;19)/E2A-PBX1
Clinical and biological presentation. Patients with t(1;19)/E2A-PBX1 did not differ notably from patients with other B-cell ALLs (Table 2) . Immunophenotypic characteristics are presented in Table 3 . Blasts from all patients expressed CD19 and CD10. The majority of cases (58%) was constituted of pre-B EGIL B-III cases with intracytoplasmic mu chains. There was no expression of CD34 but all tested cases (23/24) expressed HLA-DR. An aberrant myeloid marker (CD13) was present in one case.
Outcome. In the group with t(1;19)/E2A-PBX1, the rate of leukemic resistance was lower than in other B-cell ALLs groups (respectively 4, 12 and 23%, P ¼ 0.06). Although not significant, there was a trend to an increased proportion of patients with t(1;19)/E2A-PBX1 achieving CR after the first induction course (87% versus 76% and 75% for t(1;19)/E2A-PBX1, t(4;11)/MLL-AF4 and other B-cell ALLs, respectively).
Patients in CR were randomly assigned to allo-SCT, auto-SCT or maintenance chemotherapy as shown in Table 4 . With a t(1;19)/E2A-PBX1 and t(4;11)/MLL-AF4 ALL N Vey et al median follow-up of 50 months, 13 patients are alive including nine in continuous CR. Five-year DFS was 39711% in the group with t(1;19)/E2A-PBX1. Patients in the allo-SCT group had a better DFS (63714%) than patients assigned to auto-SCT (16715%) or maintenance chemotherapy arms (0%) but the difference did not reach statistical significance (P ¼ 0.14). The comparison of DFS between allo-SCT and non allo-SCT is shown in Figure 2 .
Molecular characteristics. Patients with t(1;19)/E2A-PBX1
were identified by both cytogenetics and PCR in 18 patients (75%), by PCR alone in five patients (20%) and by cytogenetics alone in one patient (5%). Diagnostic RQ-PCR data were available for nine patients. The mean NCN for E2A-PBX1 was 3.2 (2.5-3.9), with no correlation with clinical outcome. On day 30, seven patients had available RT-PCR data. Of the four patients who were positive, two relapsed and two are in CCR. Only one out of the three patients with negative RT-PCR is in CCR. No follow-up RQ-PCR data are available.
Discussion
In this study, we have analyzed the clinical presentation and outcome of adult patients with B-cell ALL harboring t(1;19)/E2A-PBX1 or t(4;11)/MLL-AF4 treated in the LALA-94 protocol. It represents one of the largest series of adult patients with these translocations reported so far. Our results confirm the poor outcome of these patients even when using intensive chemotherapy approaches. Only allogeneic transplantation can provide durable DFS in approximately 60% of these patients. Translocation t(1;19)/E2A-PBX1 and t(4;11)/MLL-AF4 are the most frequent cytogenetic abnormalities encountered in adults with Philadelphia-negative B-cell ALL. Using a combination of conventional cytogenetics and RT-PCR that could be performed in 814 cases included in the national prospective LALA-94 study, t(1;19)/E2A-PBX1 was seen in 4% and t(4;11)/MLL-AF4 was seen in 6% of ALLs.
In children with ALL, t(1;19) is seen in 5-6% of patients overall and represents 25% of B-cell ALL. 16, 26 In adults, the incidence of t(1;19)/E2A-PBX1 is lower, not exceeding 3%. 9, 11, 16 Translocation t(1;19) fuses the E2A transcription factor gene located on chromosome 19 to PBX1, an homeobox gene located on chromosome 1. 26 The fusion transcript produced by the translocation can be identified using RT-PCR. 27 In children, the presence of t(1;19)/E2A-PBX1 is associated with high WBC counts, organomegaly, CNS disease and CD10 þ pre-B phenotype. 16, 28 This was not the case in our series of adults with t(1;19)/E2A-PBX1 who did not display a specific clinical presentation. Interestingly, unlike previous reports, 27 we found a 80% consistency between cytogenetics and molecular biology.
In our study as in prior reports in children and adults, there is virtually no primary resistance to chemotherapy in this group and CR rates range from 90 to 100%. 9, 11, 29 However, despite this high CR rate, the long-term outcome is poor. In children, the use of intensified chemotherapy in recent protocols has contributed to improving the patients outcome and the presence of t(1;19) is no longer associated to a poor prognosis. 17 In adults, however, most of the studies of t(1;19)/E2A-PBX1 have shown poor long-term outcome. In the GFCH study, 11 the 3-year DFS was 20% and in the GIMEMA study, only four out of 10 patients achieved long-term DFS. 29 Based on these results, the patients with t(1;19)/E2A-PBX1 included in the LALA-94 protocol were assigned to the high-risk group and were therefore scheduled to receive an intensified post-remission therapy. 18 With this strategy, we observed an improvement of the 5-year DFS which was 39%. However, this improvement was essentially due to allogeneic SCT which was associated to a 63% 3-year DFS as compared to 33 and 0%, respectively, for the autologous SCT and maintenance chemotherapy arms (P ¼ 0.06). Unlike in the pediatric experience, chemotherapy intensification was not sufficient to impact significantly on the outcome of adults with t(1;19)/E2A-PBX1. The discrepancy between children and adults may be explained by differences in the biology of ALL in these two age groups but also by differences in treatment. Our group recently reported that adolescents and young adults with ALL had a better outcome when treated using the FRALLE pediatric protocol as compared to those treated with the adult LALA-94 protocol. 30 Several reasons explaining these differences have been evoked. They include differences in the drugs used (e.g., L-asparaginase) or differences in treatment compliance resulting in decreased dose-intensity in adults. 31 The t(4;11) translocation results in the fusion of the MLL gene on chromosome 11q23 and the AF4 gene on chromosome 4.
32
Translocation t(4;11) which is the most frequent cytogenetic abnormality in infants is associated with high leukocyte counts, a CD10-B-I immunophenotype with frequent aberrant expression of myeloid antigens. It is associated to a specific gene expression profile involving the over expression of FLT3. 33 In our series, the incidence of t(4;11)/MLL-AF4 was 6%. This incidence which is slightly superior to other studies in adults may be due to the use of RT-PCR which was able to detect the critical rearrangement in 12% of cases with normal cytogenetics. 11 In our series, the expression level at diagnosis, quantified using RQ-PCR, did not correlate with outcome as shown in AML. 34 MRD follow-up was available in some patients. All the patients with a positive RT-PCR after induction chemotherapy relapsed. In addition, in the single informative patient analyzed using quantitative PCR, the increase of MLL-AF4 copy numbers preceded overt relapse suggesting a possible role for RQ-PCR in the monitoring of minimal residual disease in this setting. RQ-PCR amplifications of ABL and MLL-AF4 transcripts were performed on blood samples according to the EAC protocol. For each sample, results are expressed as the ratio of MLL-AF4 copy number/ABL copy number reported to diagnosis value. The sensitivity of RQ-PCR amplification for each sample was calculated as described. 23, 24 t(1;19)/E2A-PBX1 and t(4;11)/MLL-AF4 ALL N Vey et al
Patients with t(4;11)/MLL-AF4 displayed the previously described clinical presentation including high leukocyte counts and elevated LDH. Interestingly, we also found a significantly higher frequency of DIC. The prognosis of t(4;11)/MLL-AF4 is poor in adults and children. 7, [9] [10] [11] 35 In adults, CR rates range between 70 and 77% and DFS is comprised between 0 and 24%. [9] [10] [11] Better long-term outcome was reported by the GMALL group in 22 patients who had a 40% 3-year DFS. 7 Besides fluctuations from small samples, this better outcome may be due to the use of allogeneic SCT since 4/8 long-term survivors in this series had been transplanted. In our study, the patients who received allogeneic SCT had a 63% DFS that was significantly superior to other therapeutic strategies.
Our study thus confirms the poor prognosis associated with both t(1;19)/E2A-PBX1 and t(4;11)/MLL-AF4 in adults even when treated with intensive chemotherapy approaches. Only allogeneic SCT was able to overcome the poor outcome of these patients. We conclude that allogeneic SCT must be offered in first CR to these patients. However, since the number of patients suitable for an allogeneic SCT is limited, the development of new therapeutic approaches is critically needed.
